A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis

Trial Profile

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs MGL-3196 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Madrigal Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2017 According to a Madrigal Pharmaceuticals media release, the on-going study remains blinded. Results at 36-weeks are expected in the second quarter of 2018.
    • 06 Dec 2017 Top-line results presented in a Madrigal Pharmaceuticals media release.
    • 06 Dec 2017 Primary endpoint (Change from baseline in hepatic fat fraction assessed by MRI-PDFF) has been met according to a Madrigal Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top